Systemic Efficacy with Oncolytic Virus Therapeutics: Clinical Proof-of-Concept and Future Directions
2007; American Association for Cancer Research; Volume: 67; Issue: 2 Linguagem: Inglês
10.1158/0008-5472.can-06-2871
ISSN1538-7445
Autores Tópico(s)Cancer Research and Treatments
ResumoAbstract Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed. [Cancer Res 2007;67(2):429–32]
Referência(s)